护肝化纤方联合拉米夫定对慢性乙型肝炎肝纤维化指标的影响

Effect of huganhuaxianfang combined with lamivudine on the indices of hepatic fibrosis in chronic hepatitis B

目的:观察护肝化纤方联合拉米夫定抗肝纤维化的临床疗效。方法:以临床诊断为慢乙肝肝纤维化患者165例为观察对象,分为3组,每组55例,设安慰对照组,拉米夫定组,联合用药组,分别予安慰剂(西利宾胺),拉米夫定,护肝化纤方中药煎剂联合拉米夫定,3月为一疗程,连服2疗程,观察治疗前后血清学指标肝纤维化四项(透明质酸HA、层粘连蛋白LN、Ⅳ型胶原CⅣ、Ⅲ型前胶原氨基端肽PⅢNP)和肝脏彩色多普勒超声检查。结果:各组55例患者全部坚持服药6个月,肝纤维化四项指标均低于治疗前,肝脏彩色多普勒超声图像指标得以改善,联合组下降更加明显,经配对样本t检验有统计学意义。结论:护肝化纤方联合拉米夫定能有效降低慢性肝炎患者的血清纤维化指标和肝脏彩色多普勒超声图像指标。

Objective：To study the clinical curative effect of huganhuaxianfang combined with lamivudine against hepatic fibrosis. Methods：165 cases of chronic hepatitis B with hepatic fibrosis were used as observation subjects,and divided into control group,lamivudine group and associated administration group,with 55 cases in each group.They were treated with placebo （siybin-N-methylglucamine）, lamivudine and huganhuaxianfang combined with lamivudine respectively,for 2 courses of treatment,a course of treatment was 3 months. Four items of serological indices （including HA ,LN ,CIV and P Ⅲ NP） were detected in all patients before and after treatment,and color Doppler ultrasonography was performed.Results：There were significant differences among the three groups by t test （P〈0.05）.Conclusion： Huganhuaxianfang combined with lamivudine can effectively reduce the indices of serum fibrosis and color Doppler ultrasound imaging of liver in patients with chronic hepatitis B.